Can fostatinib prevent breast cancer recurrence or metastasis? How effective is it in breast cancer treatment?

Fostamatinib (Fostamatinib) is a Syk (tyrosine kinase) inhibitor, mainly used to treat chronic immune thrombocytopenia (ITP) and rheumatoid arthritis (RA). It interferes with the signal transmission of the immune system by inhibiting the activity of Syk kinase and reduces the attack of immune cells on autologous tissues. The potential of fostatinib in the treatment of breast cancer is still in the research stage and has not yet been established as a routine treatment.

Currently, research on fostatinib in breast cancer is limited. Preliminary clinical studies and laboratory studies indicate that the role of Syk kinase in the tumor microenvironment may be closely related to breast cancer progression and metastasis. SykKinase is an important component of immune cell signaling. It plays a promoting role in the proliferation, migration and infiltration of tumor cells. Therefore, inhibiting Syk kinase may help slow or prevent tumor growth and metastasis.

Fostatinib may have a certain impact on the immune microenvironment of breast cancer patients by inhibitingSykkinase. Breast cancer, especially triple-negative breast cancer (TNBC) and HER2-positive breast cancer, is closely related to the activation of immune cells and changes in the tumor microenvironment. Fostatinib may slow down the immunosuppressive effects in the tumor microenvironment by changing the function of immune cells, thereby reducing the proliferation and migration capabilities of tumor cells.

In preliminary studies, fostatinib was considered potentially effective in triple-negative breast cancer (TNBC), a subtype of breast cancer that is insensitive to chemotherapy, hormone therapy and HER2 targeted therapy. By interfering with the signaling between immune cells and tumor cells, fostatinib is expected to enhance the effect of chemotherapy and slow down the recurrence or metastasis of tumors.

Currently, the research on fostatinib in the treatment of breast cancer is still in the clinical trial stage. Some preliminary clinical studies and small-scale trial results show that the inhibitory effect of fostatinib on breast cancer is relatively weak, especially in the prevention of recurrence and metastasis, and there is no significant evidence to support its efficacy. Despite this, some researchers have suggested that the combination of fostatinib and other drugs may have a certain positive impact on the treatment of breast cancer, especially in combination with immunotherapy.

Reference materials:https://go.drugbank.com/drugs/DB12010